Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors
Daiichi Sankyo and Takeda Pharmaceuticals to leverage FDA-approved test for clinical trials and drug development programs
SelectScience brings you scientific and technical takeaways from the 2018 AACR Annual Meeting
FORMA expands translational footprint in neurodegeneration with ARUK Oxford Drug Discovery Institute
First-of-its-kind hematology-based test intended to alert emergency department clinicians to the risk of developing sepsis
Boosting T cell memory may result in long-lasting and effective responses for patients treated with checkpoint blockade immunotherapies
CYC065, an inhibitor of CDK2 and CDK9 kinases, has inhibited tumor growth in some patients with advanced cancers
First human trials examine the impact of dark chocolate consumption on cognition and other brain functions
NYU school of medicine becomes the most recent cancer center to join PanFAM-1 prospective study
The trial demonstrates that first-line pembrolizumab treatment improved overall and progression-free survival rates in patients with metastatic nonsquamous non-small cell lung cancer
The primary endpoint for first-line nivolumab-ipilimumab combo trial indicates improved progression-free survival in patients with advanced non-small cell lung cancer
Expansion of circulating tumor-specific T cells after nivolumab treatment suggests systemic antitumor immunity in patients with resectable lung cancer
The FT819 CAR T cell line has the potential to be mass-produced, stored, and made readily available for cancer immunotherapy
Crizotinib yielded a high objective response rate for adult patients with ALK-positive Inflammatory myofibroblastic tumor, and a 100 percent disease control rate
Research reveals that acquired HER2 mutations confer resistance to hormone therapy in ER-positive metastatic breast cancer
